INDV Indivior Pharmaceuticals, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Indivior Pharmaceuticals, Inc. (INDV) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on October 30, 2025, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Indivior Pharmaceuticals, Inc. (INDV) (SEC CIK 1625297), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: specialty pharmaceuticals focused on addiction treatment and opioid dependence therapies
- • Emphasis on SUBLOCADE growth driving expected decline in U.S. revenue share from international markets this year
Risk Factors
- • FDA-required 2022 label change on SUBOXONE Film due to dental injury risk triggering ongoing product liability lawsuits
- • Exposure to U.K. Financial Services and Markets Act 2000 claims over alleged misleading disclosure about SUBOXONE product-hopping scheme
Management Discussion & Analysis
- • Revenue increased by $87M in 2025 vs $28M in 2024 from prior year performance obligations adjustments
- • No profitability or operating margin figures disclosed in the text
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • No revenue or profitability details disclosed in this MD&A excerpt
- • No segment or product line performance data provided
Risk Factors
- • New regulatory risk from 2025 OBBBA law, potentially limiting patient eligibility and treatment access for OUD starting 2027-2028
- • Material update: CMS finalized Marketplace Integrity and Affordability Regulation in June 2025, changing ACA open enrollment and premium tax credit eligibility
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • Indivior issued convertible notes (144A private placement) to qualified institutional buyers — not publicly offered
- • Max 16,202,200 common shares issuable upon conversion, representing meaningful potential dilution
Item 1.02: Termination of a Material Definitive Agreement
- • Full prepayment of all outstanding principal, accrued interest, and fees under the Note Purchase Agreement on March 17, 2026
- • Facility originated November 4, 2024, with Piper Sandler Finance LLC as Administrative Agent; terminated same day as prepayment
Item 8.01: Other Events
- • Indivior pricing 0.625% convertible senior notes due 2031 — unusually low coupon signals strong investor demand or significant equity conversion premium
- • Convertible structure means potential shareholder dilution if notes convert to common stock at maturity or trigger conditions
Annual Reports Archive10-K
AI-powered analysis of Indivior Pharmaceuticals, Inc. (INDV) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Indivior Pharmaceuticals, Inc. (INDV) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Indivior Pharmaceuticals, Inc. (INDV) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $901.0M | $1.1B | $1.2B | $1.2B |
| Gross Profit | — | $919.0M | $957.0M | $994.0M |
| Operating Income | — | -$156.0M | $32.0M | $262.0M |
| Net Income | — | -$129.0M | $2.0M | $210.0M |
| Gross Margin | — | 84.1% | 80.6% | 80.2% |
| Op. Margin | — | -14.3% | 2.7% | 21.1% |
| Net Margin | — | -11.8% | 0.2% | 16.9% |
| Balance Sheet | ||||
| Total Assets | — | $1.8B | $1.3B | $1.2B |
| Equity | -$20.0M | -$191.0M | -$348.0M | -$98.0M |
| ROE | — | 67.5% | -0.6% | -214.3% |
Source: XBRL financial data from Indivior Pharmaceuticals, Inc. (INDV) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 30, 2026 | — | — | — |
8-K | Mar 17, 2026 | — | Analysis | — |
8-K | Mar 13, 2026 | — | Analysis | — |
8-K | Mar 12, 2026 | — | Analysis | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 26, 2026 | — | Analysis | — |
8-K | Jan 26, 2026 | — | — | |
8-K | Jan 8, 2026 | — | — | |
8-K | Dec 22, 2025 | — | — | |
8-K | Dec 18, 2025 | — | — | |
8-K | Dec 15, 2025 | — | — | |
10-Q | Oct 30, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Jul 31, 2025 | Jun 30, 2025 | — | |
10-Q | May 1, 2025 | Mar 31, 2025 | — | |
10-K | Mar 3, 2025 | Dec 31, 2024 | — | |
20-F | Mar 6, 2024 | Dec 31, 2023 | — |
Frequently Asked Questions
What are the latest INDV SEC filings in 2026?
Indivior Pharmaceuticals, Inc. (INDV) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did INDV file its most recent 10-K annual report?
Indivior Pharmaceuticals, Inc. (INDV) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view INDV 10-Q quarterly reports?
Indivior Pharmaceuticals, Inc. (INDV)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every INDV 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has INDV filed recently?
Indivior Pharmaceuticals, Inc. (INDV)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find INDV insider trading activity (Form 4)?
SignalX aggregates every INDV Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does INDV file with the SEC?
Indivior Pharmaceuticals, Inc. (INDV) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new INDV filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Indivior Pharmaceuticals, Inc. (INDV).
What is INDV's SEC CIK number?
Indivior Pharmaceuticals, Inc. (INDV)'s SEC CIK (Central Index Key) number is 1625297. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1625297 to look up all INDV filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find INDV return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Indivior Pharmaceuticals, Inc. (INDV) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Indivior Pharmaceuticals, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 16+ filings.